Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2017’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)

The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects

The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

AnaMar AB

Angion Biomedica Corp

arGentis Pharmaceuticals LLC

Bayer AG

Biogen Inc

BiOrion Technologies BV

BLR Bio LLC

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Covis Pharmaceuticals Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fibrocell Science Inc

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

iBio Inc

Inventiva

Kadmon Corp LLC

MedImmune LLC

miRagen Therapeutics Inc

Patagonia Pharmaceuticals LLC

PDX Pharmaceuticals LLC

Peptinov SAS

ProMetic Life Sciences Inc

Ribomic Inc

Samumed LLC

Sanofi

Stemline Therapeutics Inc

viDA Therapeutics Inc

VivaCell Biotechnology Espana SL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Systemic Sclerosis (Scleroderma) - Overview 8

Systemic Sclerosis (Scleroderma) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 23

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31

Allergan Plc 31

AnaMar AB 31

Angion Biomedica Corp 32

arGentis Pharmaceuticals LLC 32

Bayer AG 33

Biogen Inc 33

BiOrion Technologies BV 34

BLR Bio LLC 34

Boehringer Ingelheim GmbH 35

Bristol-Myers Squibb Company 35

Covis Pharmaceuticals Inc 36

CSL Ltd 36

Cumberland Pharmaceuticals Inc 37

F. Hoffmann-La Roche Ltd 37

Fibrocell Science Inc 38

GenKyoTex SA 38

Gilead Sciences Inc 39

GlaxoSmithKline Plc 39

iBio Inc 40

Inventiva 40

Kadmon Corp LLC 41

MedImmune LLC 41

miRagen Therapeutics Inc 42

Patagonia Pharmaceuticals LLC 42

PDX Pharmaceuticals LLC 43

Peptinov SAS 43

ProMetic Life Sciences Inc 44

Ribomic Inc 44

Samumed LLC 45

Sanofi 45

Stemline Therapeutics Inc 46

viDA Therapeutics Inc 46

VivaCell Biotechnology Espana SL 47

Systemic Sclerosis (Scleroderma) - Drug Profiles 48

abatacept - Drug Profile 48

acALY-18 - Drug Profile 55

ambrisentan - Drug Profile 56

ANG-3070 - Drug Profile 58

ARG-201 - Drug Profile 59

belimumab - Drug Profile 61

BLR-200 - Drug Profile 68

BOT-191 - Drug Profile 69

C-1889 - Drug Profile 70

C-82 - Drug Profile 72

CM-101 - Drug Profile 73

dimethyl fumarate DR - Drug Profile 74

factor XIII (human) - Drug Profile 79

FCX-013 - Drug Profile 80

GKT-831 - Drug Profile 81

GSK-2330811 - Drug Profile 84

IBIOCFB-03 - Drug Profile 85

ifetroban sodium - Drug Profile 87

IVA-337 - Drug Profile 89

JBT-101 - Drug Profile 91

KD-025 - Drug Profile 97

M-10 - Drug Profile 102

MEDI-7734 - Drug Profile 103

miRNA-29 - Drug Profile 104

Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 105

MRG-201 - Drug Profile 106

nintedanib - Drug Profile 108

nitroglycerin - Drug Profile 119

onabotulinumtoxinA - Drug Profile 121

PAT-048 - Drug Profile 126

PATS-03 - Drug Profile 127

PBI-4050 - Drug Profile 128

PDX-002 - Drug Profile 135

PPV-06 - Drug Profile 136

RBM-006 - Drug Profile 137

riociguat - Drug Profile 138

rituximab biosimilar - Drug Profile 144

RP-182 - Drug Profile 145

SAR-100842 - Drug Profile 146

SAR-156597 - Drug Profile 147

SAR-317461 - Drug Profile 148

SM-04755 - Drug Profile 149

Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 150

Small Molecules to Antagonize 5-HT2B for Fibrosis - Drug Profile 151

Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 152

terguride - Drug Profile 153

tocilizumab - Drug Profile 154

TRX-101 - Drug Profile 164

VCE-0048 - Drug Profile 165

VEDA-1209 - Drug Profile 166

VTI-1000 Series - Drug Profile 167

Wnt-001 - Drug Profile 168

Systemic Sclerosis (Scleroderma) - Dormant Projects 169

Systemic Sclerosis (Scleroderma) - Discontinued Products 171

Systemic Sclerosis (Scleroderma) - Product Development Milestones 172

Featured News & Press Releases 172

Appendix 185

Methodology 185

Coverage 185

Secondary Research 185

Primary Research 185

Expert Panel Validation 185

Contact Us 185

Disclaimer 186

List of Tables

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Allergan Plc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by AnaMar AB, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Angion Biomedica Corp, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by arGentis Pharmaceuticals LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Bayer AG, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Biogen Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by BiOrion Technologies BV, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by BLR Bio LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Covis Pharmaceuticals Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by CSL Ltd, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Cumberland Pharmaceuticals Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Fibrocell Science Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by GenKyoTex SA, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Gilead Sciences Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by GlaxoSmithKline Plc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by iBio Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Inventiva, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Kadmon Corp LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by MedImmune LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by miRagen Therapeutics Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Patagonia Pharmaceuticals LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by PDX Pharmaceuticals LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Peptinov SAS, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by ProMetic Life Sciences Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Ribomic Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Samumed LLC, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Sanofi, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Stemline Therapeutics Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by viDA Therapeutics Inc, H1 2017

Systemic Sclerosis (Scleroderma) – Pipeline by VivaCell Biotechnology Espana SL, H1 2017

Systemic Sclerosis (Scleroderma) – Dormant Projects, H1 2017

Systemic Sclerosis (Scleroderma) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Systemic Sclerosis (Scleroderma) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports